Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reveal a balanced perspective, with users noting the high success rate of PCI but emphasizing the trial's limitations like low power and crossover issues, using phrases like 'hard to know what to take away' and 'significant limitations,' which show cautious engagement, while mentions of 'no difference in MACE' reflect consensus on the core findings.
Most discussions acknowledge the trial's findings that PCI success rates are high but show no significant difference in major outcomes, indicating general agreement on the results.
The discussion around trial details, such as crossover rates, study limitations, and the clinical relevance of PCI for CTO, suggests high interest among the participants.
Participants reference specific aspects of the study, share opinions on its limitations, and discuss implications, indicating a moderate depth of engagement.
The posts highlight the trial's influence on clinical decision-making and ongoing debates in the cardiology community, reflecting a modest but meaningful impact.
At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitations of the trial. Hard to know what to take away from this, unfortunately. https://t.co/h7MQilna8a
DECISION-CTO -#PCI en #CTO sin diferencias en eventos CV vs no revascularización -Estudio abierto, mucho cross over (19%) y poco reclutamiento -90% tasa de éxito en PCI a CTO Vía @CircAHA https://t.co/zpiwh5ytL3 https://t.co/tSoQoop81t
DECISION-CTO trial: RCT Evaluating #PCI for the Treatment of Chronic Total Occlusion (#CTO)
is it reliable to use noninferiority design for DECISION-CTO, @ihtanboga @ADAlthousePhD @boback @venkmurthy @MaartenvSmeden @CircAHA @SABOURETCardio @drjohnm https://t.co/wlJLdqqLvN https://t.co/U0IxMFvzkV
#CircOnTheRun Podcast with Prof. Seung-Whan Lee & associate editor, Dr. Manos Brilakis on Medical therapy vs PCI for Chronic Total Occlusion: The DECISION-CTO Trial https://t.co/yztp9k6SSP Featured Paper: https://t.co/CS92a9Q7pm https://t.co/fUzrs2CF5k
@davidbartov @jedicath @LAzzaliniMD @AntoniousAttall @ShariqShamimMD @mmamas1973 @GEICC3 @rickytiago @hectortamezmd @MohanedEgred @HadyLichaaMD If you look at the DECISION-CTO trial, about 1/4 of the pts who were enrolled in that trial were exactly that population-- pts who presented with either an MI or unstable angina and were randomized after successful treatment of a non-CTO culprit lesion. https://t.co/WThlsn2w0s
This week in Cardiology, Dr. John Mandrola discusses reader feedback on LGE pre-ICDs, PFA for AF ablation, and endovascular approaches for chronic total occlusions. This podcast is designed for healthcare professionals…
Stopping oral anticoagulation after AF ablation is a core issue, alongside discussions on paradoxes such as the smokers paradox and chronic total occlusion PCI. Dr. John Mandrola reviews these topics in this week's…
@jedicath @rallamee @rwyeh @GreggWStone @mbmcentegart @jcspratt @SVRaoMD @colum_owens A lot of the patients enrolled in DECISION CTO were exactly this population. https://t.co/klXRcO88sj
RT @djc795: @davidbartov @jedicath @LAzzaliniMD @AntoniousAttall @ShariqShamimMD @mmamas1973 @GEICC3 @rickytiago @hectortamezmd @MohanedEgr…
@davidbartov @jedicath @LAzzaliniMD @AntoniousAttall @ShariqShamimMD @mmamas1973 @GEICC3 @rickytiago @hectortamezmd @MohanedEgred @HadyLichaaMD If you look at the DECISION-CTO trial, about 1/4 of the pts who were enrolled in that trial were exactly that population-- pts who presented with either an MI or unstable angina and were randomized after successful treatment of a non-CTO culprit lesion. https://t.co/WThlsn2w0s
@evandrofilhobr @ShariqShamimMD @AntoniousAttall @aspergian1 @chipkaminsky @cardioPCImom @LAzzaliniMD @perc_surgeon @BaoGTran @serioustaurean https://t.co/lAg5Rk8KZR a very limited use intervention for non LAD CTO in my opinion and only among those with severe angina.
RT @gonzaeperez: DECISION-CTO -#PCI en #CTO sin diferencias en eventos CV vs no revascularización -Estudio abierto, mucho cross over (19%)…
Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion | Circulation https://t.co/xEHUh08EY0
Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion: The DECISION-CTO trial @MDLinx https://t.co/T4y5WPbGfR
RT @gonzaeperez: DECISION-CTO -#PCI en #CTO sin diferencias en eventos CV vs no revascularización -Estudio abierto, mucho cross over (19%)…
RT @gonzaeperez: DECISION-CTO -#PCI en #CTO sin diferencias en eventos CV vs no revascularización -Estudio abierto, mucho cross over (19%)…
RT @gonzaeperez: DECISION-CTO -#PCI en #CTO sin diferencias en eventos CV vs no revascularización -Estudio abierto, mucho cross over (19%)…
DECISION-CTO trial Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion | Circulation https://t.co/EDMjujspDw
RT @gonzaeperez: DECISION-CTO -#PCI en #CTO sin diferencias en eventos CV vs no revascularización -Estudio abierto, mucho cross over (19%)…
RT @gonzaeperez: DECISION-CTO -#PCI en #CTO sin diferencias en eventos CV vs no revascularización -Estudio abierto, mucho cross over (19%)…
RT @gonzaeperez: DECISION-CTO -#PCI en #CTO sin diferencias en eventos CV vs no revascularización -Estudio abierto, mucho cross over (19%)…
RT @gonzaeperez: DECISION-CTO -#PCI en #CTO sin diferencias en eventos CV vs no revascularización -Estudio abierto, mucho cross over (19%)…
RT @gonzaeperez: DECISION-CTO -#PCI en #CTO sin diferencias en eventos CV vs no revascularización -Estudio abierto, mucho cross over (19%)…
RT @gonzaeperez: DECISION-CTO -#PCI en #CTO sin diferencias en eventos CV vs no revascularización -Estudio abierto, mucho cross over (19%)…
RT @gonzaeperez: DECISION-CTO -#PCI en #CTO sin diferencias en eventos CV vs no revascularización -Estudio abierto, mucho cross over (19%)…
DECISION-CTO -#PCI en #CTO sin diferencias en eventos CV vs no revascularización -Estudio abierto, mucho cross over (19%) y poco reclutamiento -90% tasa de éxito en PCI a CTO Vía @CircAHA https://t.co/zpiwh5ytL3 https://t.co/tSoQoop81t
Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion | Circulation https://t.co/Z7aZR71wMG
#CircOnTheRun Podcast with Prof. Seung-Whan Lee & associate editor, Dr. Manos Brilakis on Medical therapy vs PCI for Chronic Total Occlusion: The DECISION-CTO Trial https://t.co/yztp9k6SSP Featured Paper: https://t.co/CS92a9Q7pm https://t.co/fUzrs2CF5k
RT @CircAHA: DECISION-CTO trial: RCT Evaluating #PCI for the Treatment of Chronic Total Occlusion (#CTO)
Randomized Trial Evaluating #Percutaneous #Coronary Intervention for the Treatment of Chronic Total Occlusion | #Circulation https://t.co/eTLIn5L8Es
DECISION-CTO trial: RCT Evaluating #PCI for the Treatment of Chronic Total Occlusion (#CTO)
Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion: The DECISION-CTO Trial | Circulation https://t.co/pvPr1wKmtS
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion: The DECISION-CTO Trial | Circulation https://t.co/0z1u1Kvbuz
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion: The DECISION-CTO Trial https://t.co/O23Gfr0XNk
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
RT @rwyeh: At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitat…
At long last, the DECISION CTO trial is published. The authors deserve credit for opening acknowledging the significant limitations of the trial. Hard to know what to take away from this, unfortunately. https://t.co/h7MQilna8a
is it reliable to use noninferiority design for DECISION-CTO, @ihtanboga @ADAlthousePhD @boback @venkmurthy @MaartenvSmeden @CircAHA @SABOURETCardio @drjohnm https://t.co/wlJLdqqLvN https://t.co/U0IxMFvzkV
RT @AlesqQuadros: DECISION CTO published almost 2 y after presentation. PCI feasible with high success rates, no difference in MACE, but st…
DECISION CTO published almost 2 y after presentation. PCI feasible with high success rates, no difference in MACE, but study imited by low power for clinical endpoints and high crossover.#CTO #CardioTwitter #RadialFirst https://t.co/mWD48owF74
RY
GP
C
AK
DM
L
DK
MZ
SA
AE
ER
S
JV
JA
S
RV
LR
PL
DV
AV
EM
CS
JH
LU
TA
AG
J
MM
TK
S
VP
MM
JM
V
AH
RG
RB
JW
RK
GV
Z
JS
SP
HM
DV
TH
BB
PK
R
AQ